Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
A legfontosabb adatok
- Ki végzi
- The First Affiliated Hospital of Soochow University
- Hol
- Suzhou (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 400 fő, tervezett
- Kezdés
- 2024. dec. 1.
- Tervezett befejezés
- 2026. jún. 1.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoport
- A vizsgált kezelések
- rTMS combined with Live Probiotic tablet
- rTMS combined placebo
- shamrTMS combined with Live Probiotic tablet
- shamrTMS combined placebo group
- A regiszteradat frissítve
- 2025. május 7.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with irritable bowel syndrome with diarrhea (IBS-D). It tests magnetic brain stimulation (rTMS) and a live probiotic tablet, alone or together.
- Életkor
- 18 to 70 years
- Nem
- All sexes
- A betegség stádiuma
- Irritable bowel syndrome by the Rome IV criteria, lasting more than 6 months. The IBS symptom severity score at the start must be at least 75. No other disease or test change may explain the bowel symptoms.
- Korábbi kezelés
- No drug treatment for IBS (except emergency treatment) for at least 2 weeks before the trial starts. People who had surgery on the anus, intestines or abdomen cannot join.
A részvétel fő kizáró okai
- Severe liver, kidney, blood, heart or brain blood vessel disease, or mental illness that strongly affects thinking
- Clear physical bowel disease, diabetes, overactive thyroid or other diseases that affect gut movement
- Regular use of drugs that affect gut movement or function
- Pregnancy, breastfeeding, or less than 12 months since giving birth
- Pacemaker, metal allergy, or severe fear of needles
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Must meet the diagnostic criteria for Irritable Bowel Syndrome of Rome IV
- Age range between 18-70 years
- The duration of the disease is more than 6 months
- There are no pathologic abnormalities or biochemical changes that could explain the bowel-related symptoms
- The IBS symptom severity score at baseline must not be less than 75
- No pharmacological treatment (excluding emergency treatment) for IBS for at least 2 weeks prior to the start of treatment; no concurrent participation in other clinical programs
- Voluntarily sign the relevant informed consent form and voluntarily participate in this clinical project
Ki nem vehet részt
- The presence of the following conditions affecting the efficacy or safety judgment: ① regular use of preparations and drugs affecting gastrointestinal dynamics or function; ② treatment with other treatments and drugs that may affect the results of the judgment
- Those who suffer from severe liver, kidney, hematopoietic system diseases, cardiovascular and cerebrovascular diseases, and psychiatric diseases that significantly affect cognitive function
- Patients with clear organic diseases of the intestinal tract; patients with diabetes, hyperthyroidism and other systemic diseases that affect the digestive tract dynamics; patients who have had a history of surgery on the anus and intestines or the abdomen
- Patients with severe fear of needles, metal allergies or sensitivities, or those with pacemakers
- Be less than 18 years old or more than 70 years old
- Those who are pregnant, breastfeeding or less than 12 months after delivery
- Patients who do not comply with the randomized assignment to the treatment group or have a tendency to be unstable such as poor compliance
- Patients who are participating in other research projects
- Those who do not want to sign the informed consent form
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 70 év között vagy?
Helyszínek itt: Kína
- The First Affiliated Hospital of Soochow UniversitySuzhou, KínaContact: Wu ShuangjieRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
To evaluate the overall efficacy of repeated Transcranial Magnetic Stimulation(rTMS) combined with a Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
A teljes eredeti leírásKevesebb
Methods:
Clinical efficacy evaluation of TMS combined with Live Probiotic tablet for chronic diarrhea in IBS patients. The 400 IBS patients who meet the recruitment criteria for the clinical study will be randomized into 100 patients in rTMS combined with Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live), rTMS combined placebo, shamrTMS combined with Live Probiotic tablet(Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) and shamrTMS combined placebo group. Corresponding treatment was given for 2 week, rTMS group received 1 Hz/s, 20 min for 2 week; Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week, shamrTMS group received 0 Hz/s, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week. Clinical assessment included symptoms, stool traits, mood, and sleep.
2. Study on the mechanism of using intestinal flora data to evaluate the treatment of chronic diarrhea in IBS patients. 30 cases each were included in the 4 groups of IBS-eligible patients, and repeated transcranial magnetic stimulation treatment was given to the patient group for 2 week, and the patient group underwent the assessment of investigating the quantity and metabolic changes of the intestinal flora in feces before and after the treatment.
A vizsgálat 4 csoportja
- rTMS combined with Live Probiotic tabletA vizsgált kezelés
rTMS combined with Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live). rTMS group received 1 Hz/s, 20 min for 2 week; Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week.
- rTMS combined placeboA vizsgált kezelés
rTMS combined placebo rTMS group received 1 Hz/s, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week.
- shamrTMS combined with Live Probiotic tabletA vizsgált kezelés
shamrTMS combined with Live Probiotic tablet(Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week, shamrTMS group received 0 Hz/s, 20 min for 2 week.
- shamrTMS combined placebo groupEgyéb csoport
shamrTMS combined placebo group shamrTMS group received 0 Hz/s, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT06960369: ki vehet részt
- A regiszteradat frissítve
- 2025. május 7.